Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Non-Hodkgin's Lymphoma (NHL)
Arpita P Gandhi(Oregon Health & Science University), Scott D. Rowley(Johns Hopkins Hospital), Brenda Díaz(Hackensack University Medical Center), Phyllis McKiernan(Hackensack University Medical Center), Tatyana Feldman(Hackensack University Medical Center), Andrew L. Pecora(Hackensack University Medical Center), Pritish K. Bhattacharyya(Hackensack University Medical Center), Stuart L. Goldberg(Hackensack University Medical Center), Melissa Baker(Hackensack University Medical Center), André Goy(Hackensack University Medical Center), Anthony R. Mato(University of Pennsylvania), Themba Nyirenda(Hackensack University Medical Center), Michèle L. Donato(The University of Texas Health Science Center at Houston), David H. Vesole(Hackensack University Medical Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k